These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 19734938

  • 1. The neuroblastoma tumour-suppressor TrkAI and its oncogenic alternative TrkAIII splice variant exhibit geldanamycin-sensitive interactions with Hsp90 in human neuroblastoma cells.
    Farina AR, Tacconelli A, Cappabianca L, Cea G, Chioda A, Romanelli A, Pensato S, Pedone C, Gulino A, Mackay AR.
    Oncogene; 2009 Nov 19; 28(46):4075-94. PubMed ID: 19734938
    [Abstract] [Full Text] [Related]

  • 2. Geldanamycin inhibits tyrosine phosphorylation-dependent NF-kappaB activation.
    Crèvecoeur J, Merville MP, Piette J, Gloire G.
    Biochem Pharmacol; 2008 Jun 01; 75(11):2183-91. PubMed ID: 18455150
    [Abstract] [Full Text] [Related]

  • 3. Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma.
    Tacconelli A, Farina AR, Cappabianca L, Gulino A, Mackay AR.
    Future Oncol; 2005 Oct 01; 1(5):689-98. PubMed ID: 16556046
    [Abstract] [Full Text] [Related]

  • 4. Retrograde TrkAIII transport from ERGIC to ER: a re-localisation mechanism for oncogenic activity.
    Farina AR, Cappabianca L, Ruggeri P, Gneo L, Maccarone R, Mackay AR.
    Oncotarget; 2015 Nov 03; 6(34):35636-51. PubMed ID: 26415233
    [Abstract] [Full Text] [Related]

  • 5. The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII.
    Farina AR, Cappabianca L, Ruggeri P, Gneo L, Pellegrini C, Fargnoli MC, Mackay AR.
    J Exp Clin Cancer Res; 2018 Jun 18; 37(1):119. PubMed ID: 29914559
    [Abstract] [Full Text] [Related]

  • 6. TrkAIII expression in the thymus.
    Tacconelli A, Farina AR, Cappabianca L, Cea G, Panella S, Chioda A, Gallo R, Cinque B, Sferra R, Vetuschi A, Campese AF, Screpanti I, Gulino A, Mackay AR.
    J Neuroimmunol; 2007 Feb 18; 183(1-2):151-61. PubMed ID: 17241672
    [Abstract] [Full Text] [Related]

  • 7. Geldanamycin interferes with the 90-kDa heat shock protein, affecting lipopolysaccharide-mediated interleukin-1 expression and apoptosis within macrophages.
    Hsu HY, Wu HL, Tan SK, Li VP, Wang WT, Hsu J, Cheng CH.
    Mol Pharmacol; 2007 Jan 18; 71(1):344-56. PubMed ID: 16868182
    [Abstract] [Full Text] [Related]

  • 8. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma.
    Tacconelli A, Farina AR, Cappabianca L, Desantis G, Tessitore A, Vetuschi A, Sferra R, Rucci N, Argenti B, Screpanti I, Gulino A, Mackay AR.
    Cancer Cell; 2004 Oct 18; 6(4):347-60. PubMed ID: 15488758
    [Abstract] [Full Text] [Related]

  • 9. The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.
    Jeon YK, Park CH, Kim KY, Li YC, Kim J, Kim YA, Paik JH, Park BK, Kim CW, Kim YN.
    J Pathol; 2007 Oct 18; 213(2):170-9. PubMed ID: 17768706
    [Abstract] [Full Text] [Related]

  • 10. Resistance to geldanamycin-induced apoptosis in differentiated neuroblastoma SH-SY5Y cells.
    Shen JH, Zhang Y, Wu NH, Shen YF.
    Neurosci Lett; 2007 Mar 06; 414(2):110-4. PubMed ID: 17293044
    [Abstract] [Full Text] [Related]

  • 11. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells.
    Schumacher JA, Crockett DK, Elenitoba-Johnson KS, Lim MS.
    Proteomics; 2007 Aug 06; 7(15):2603-16. PubMed ID: 17610208
    [Abstract] [Full Text] [Related]

  • 12. Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.
    Jayanthan A, Fowler J, Hawkins L, Lamers F, Teja B, Incoronato A, Anderson R, Narendran A.
    J Exp Ther Oncol; 2008 Aug 06; 7(3):183-93. PubMed ID: 19066127
    [Abstract] [Full Text] [Related]

  • 13. TRAIL induces pro-apoptotic crosstalk between the TRAIL-receptor signaling pathway and TrkAIII in SH-SY5Y cells, unveiling a potential therapeutic "Achilles heel" for the TrkAIII oncoprotein in neuroblastoma.
    Gneo L, Ruggeri P, Cappabianca L, Farina AR, Di Ianni N, Mackay AR.
    Oncotarget; 2016 Dec 06; 7(49):80820-80841. PubMed ID: 27821809
    [Abstract] [Full Text] [Related]

  • 14. Molecular Characterization and Inhibition of a Novel Stress-Induced Mitochondrial Protecting Role for Misfolded TrkAIII in Human SH-SY5Y Neuroblastoma Cells.
    Cappabianca L, Ruggieri M, Sebastiano M, Sbaffone M, Martelli I, Ruggeri P, Di Padova M, Farina AR, Mackay AR.
    Int J Mol Sci; 2024 May 17; 25(10):. PubMed ID: 38791513
    [Abstract] [Full Text] [Related]

  • 15. The TrkAIII oncoprotein inhibits mitochondrial free radical ROS-induced death of SH-SY5Y neuroblastoma cells by augmenting SOD2 expression and activity at the mitochondria, within the context of a tumour stem cell-like phenotype.
    Ruggeri P, Farina AR, Di Ianni N, Cappabianca L, Ragone M, Ianni G, Gulino A, Mackay AR.
    PLoS One; 2014 May 17; 9(4):e94568. PubMed ID: 24736663
    [Abstract] [Full Text] [Related]

  • 16. The alternative TrkAIII splice variant targets the centrosome and promotes genetic instability.
    Farina AR, Tacconelli A, Cappabianca L, Cea G, Panella S, Chioda A, Romanelli A, Pedone C, Gulino A, Mackay AR.
    Mol Cell Biol; 2009 Sep 17; 29(17):4812-30. PubMed ID: 19564412
    [Abstract] [Full Text] [Related]

  • 17. Geldanamycin, a heat shock protein 90-binding agent, disrupts Stat5 activation in IL-2-stimulated cells.
    Xu W, Yu F, Yan M, Lu L, Zou W, Sun L, Zheng Z, Liu X.
    J Cell Physiol; 2004 Feb 17; 198(2):188-96. PubMed ID: 14603521
    [Abstract] [Full Text] [Related]

  • 18. The Ah receptor is a sensitive target of geldanamycin-induced protein turnover.
    Chen HS, Singh SS, Perdew GH.
    Arch Biochem Biophys; 1997 Dec 01; 348(1):190-8. PubMed ID: 9390191
    [Abstract] [Full Text] [Related]

  • 19. HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo.
    Lesko E, Gozdzik J, Kijowski J, Jenner B, Wiecha O, Majka M.
    Anticancer Drugs; 2007 Nov 01; 18(10):1173-81. PubMed ID: 17893518
    [Abstract] [Full Text] [Related]

  • 20. Theileria-induced constitutive IKK activation is independent of functional Hsp90.
    Hermann P, Dobbelaere DA.
    FEBS Lett; 2006 Sep 18; 580(21):5023-8. PubMed ID: 16938294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.